Dear Colleagues, members, students and friends of the ESS,

“The important thing is to not stop questioning. Curiosity has its own reason for existing”. For me, this quote by Albert Einstein (born in Ulm, near my university), reflects an integral spirit of our society. With an unbridled quest toward this very curiosity to question scientific dogmas, challenge clinical paradigms, practices and opinions, we, individually as well as collectively, strive for a better world.

Our current newsletter has been emblematic of that effort. One example is the recent Wiggers-Bernard Conference on sepsis modeling that brought together a superb team of scientists that critically discussed the current scientific practices and created a set of guidelines for pre-clinical sepsis (see the article by its coordinator, Marcin Osuchowski). Another great example of the above mentioned quest is the ongoing PROVIDE trial (coordinated by our president-elect Evangelos Giamarellos-Bourboulis) that incorporates an individual treatment approach as its key design element; see the preliminary report below.

Questioning is thus, invariably, a predominating motif of our upcoming ESS congress in Chania in October 8th-12th 2019. We encourage our members, especially our juniors, to embrace this exercise of challenging shock research on multiple levels through relentless questioning and inquiry. The ESS congress, together with the IFSS and Hellenic Institute for Study of Sepsis, will offer a uniquely targeted content, foster a high level of scientific dialogue and provide a splendidly relaxing environment for social interaction. In lieu of the traditional “lecture” format, the ESS/IFSS congress will rely on the Socratic concept as a central platform for exchanging scientific information and stimulating critical thinking. At this conference, attendees should not just listen; they shall actively engage with presenters and peers, contributing to the dynamic exchanges during which, science thrives and evolves the most vigorously. I am therefore, looking very much forward to welcoming you at Chania in October 2019!

We are continually in search of dedicated ESS members and new members who appreciate the common efforts of our lively society and are ready to invest some of their time to support it. Please continue to encourage your junior and senior peers to join our society.

At the end of 2018, I would like to thank each member for her/his dedication and time spent on supporting our activities. My special thanks go to the executive committee including Inge Bauer (our secretary) and Marcin Osuchowski (our treasurer) for their continuous support.

May this season bring you the blessings of peace, joy, hope and happiness!

Enjoy reading our newsletter.

Best wishes,

Markus Huber-Lang
President of ESS
**Update ESS Congress 2019, Chania**

The program of the 2019 joint ESS/IFSS Congress in Chania, Crete, will cover multiple shock/sepsis research topics of the highest scientific impact.

The synopsis of the planned scientific and social events:

**Tuesday 08th October 2019**

*The ESS Fall School on “Hemorrhagic Shock”*

For junior ESS members and students, we organize another iteration of the ESS Fall School, this time we focus on hemorrhagic shock (HS). Eminent experts in the HS field will walk the attendees through the first definition of Shock, complex clinical picture (including hands-on activities) to pre-clinical modeling of HS.

*Reception Dinner*

Attendees will be registering for the main congress event and a **common reception dinner will be organized** for all attendees, as an opportunity to encourage scientific and personal bonding in a relaxing atmosphere of a local Greek tavern.

**Wednesday 09th October 2019**

*“Hippocrates meets Sokrates” - Novum*

This year, we organize a “Hot Topic Debate Platform” to discuss the latest and hottest scientific reports. Both clinicians and basic scientists are welcome/encouraged to participate.

*“Get the clinicians back to research” joint ESS/ECTES meeting - Novum*

Participation of clinician is encouraged at this **joint ESS/ECTES session** by presenting cutting edge translational research.

*Poster sessions*

This year, we provide the **prime time** (late morning) for all poster presentations. There are no overlapping sessions/events scheduled at the time of the poster presentations. This will enable the participants to get involved in one-to-one discussions with experts and peers. As in the past, all posters will be presented in thematic blocks and scored by designated judges – a great chance to win an award!

*Dinner*

To continue scientific discussions, develop personal relationship or simply unwind and share some laughs, an informal dinner will be organized for all attendees at a local tavern.
Thursday 10th October 2019
A series of joint sessions between IFSS and various shock societies is scheduled on that day. Best speakers from around the world are teamed up for those session blocks. Not only original research but also topics inherent to various national/geographical areas will be covered.

**Guided Poster Tours - Novum**
The latest addition to our 2019 meeting: **guided poster tours for small student groups** of the ESS Fall School led by senior scientists will be arranged (prior registration is required as the participation is limited), to discuss the latest discoveries on the selected topics.

**Olympus Session**
The key junior-oriented event of each ESS congress: the **European New Investigator Award Competition (ENIAC)**. This well-attended session highlights the best science performed in the labs across the European continent; it is simultaneously very stressful (i.e. to the top five competitors) and enjoyable (to the audience). ENIAC is a coveted award that ensures a respectable scientific recognition to the winner(s) (not mentioning a decent cash award).

**Chania City Tour & Dinner - Novum**
In the afternoon, all attendees will have an opportunity to take part in a guided tour through the ancient Greek quarters in the city of Chania. The tour will be followed by dinner at a local fish restaurant. Definitely recommendable!

Friday 11th October 2019

**Shock research from the Mediterranean - Novum**
We are proud to feature the **Hellenic Institute for Study on Sepsis**, chaired by our president-elect Evangelos Giamarellos-Bourboulis; this session will present regional, cutting-edge research on systemic inflammation, sepsis and shock. Non-Greek attendees are also warmly welcome!

**Russian Shock SSSR - Novum**
A parallel session to the joint ESS/IFSS sessions is scheduled for Russian Shock SSSR. This session has been organized to enable Russian scientists/clinicians to present their work in their native language (a simultaneous translation into English will be provided).

**Collaborative Shock Research - Novum**
This afternoon session will cover the ongoing **European Collaborative Shock Research** efforts. The session will feature several active international/intra-European shock research groups and provide an update on their collaborative works.
**Past – Present – Future of Shock research - Novum**

The scientific program of the ESS/IFSS congress will close with a series of stimulating talks addressing the evolving premise of shock research and feature an discussion about “quo vadis shock research”.

**Farewell Dinner**

Our closing social event: an opportunity to actively enjoy Greek folk dance to bid farewell to all attendees and participants of the congress! It is a deserving activity for all young and younger participants; do not miss this chance to stretch your legs (and hands!) after several days of occupying chairs in various seminar rooms! You will not regret it – we guarantee it.

**Saturday 12th October 2019**

Using the momentum of a scientifically-charged atmosphere, the ESS congress will be followed by the 2nd iteration of Wiggers-Bernard Initiative on Sepsis Modeling (by invitation only) organized by the Ludwig-Boltzmann Institute (and coordinated by Marcin Osuchowski). Pre-and clinical sepsis experts will discuss future directions of animal sepsis modeling with the ultimate goal of improving translational reliability of animal-based research.

**Miscellaneous**

The ESS/IFSS congress is logistically supported by the Aegean Conferences (AC). The AC mission is to empower scientists to organize and participate in conferences that offer a uniquely targeted content, foster a high level of scientific dialogue and provide an informal environment for social interaction. In accordance to the AC Socrates concept, all attendees interact without observing the hierarchical structure (e.g. common shared space for all meals; unrestricted social event participation) and unprejudiced discussions/scientific exchange across all levels is encouraged.

**Of note**

**Multiple Poster Awards and Travel Awards** will be granted (sponsored by ESS, IFSS, and Aegean Conferences).

If you have any suggestions, please feel free to contact the ESS board any time.

Please save the date and we are looking very forward to welcoming you in Chania!

Drafted by Markus Huber-Lang

[back to contents]
<table>
<thead>
<tr>
<th>Time</th>
<th>Monday</th>
<th>Tuesday</th>
<th>Wednesday</th>
<th>Thursday</th>
<th>Friday</th>
<th>Saturday</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-08:30</td>
<td>Registration/Check-In</td>
<td>Registration/Check-In</td>
<td>Registration/Check-In</td>
<td>Registration/Check-In</td>
<td>Registration/Check-In</td>
<td>Registration/Check-In</td>
</tr>
<tr>
<td>08:30-09:00</td>
<td>Opening Session</td>
<td>Opening Session</td>
<td>Opening Session</td>
<td>Opening Session</td>
<td>Opening Session</td>
<td>Opening Session</td>
</tr>
<tr>
<td>09:00-10:30</td>
<td>Plenary Session 1</td>
<td>Plenary Session 1</td>
<td>Plenary Session 1</td>
<td>Plenary Session 1</td>
<td>Plenary Session 1</td>
<td>Plenary Session 1</td>
</tr>
<tr>
<td>10:30-11:00</td>
<td>Coffee Break</td>
<td>Coffee Break</td>
<td>Coffee Break</td>
<td>Coffee Break</td>
<td>Coffee Break</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11:00-12:30</td>
<td>Panel Session 1</td>
<td>Panel Session 1</td>
<td>Panel Session 1</td>
<td>Panel Session 1</td>
<td>Panel Session 1</td>
<td>Panel Session 1</td>
</tr>
<tr>
<td>12:30-13:30</td>
<td>Lunch</td>
<td>Lunch</td>
<td>Lunch</td>
<td>Lunch</td>
<td>Lunch</td>
<td>Lunch</td>
</tr>
<tr>
<td>13:30-15:00</td>
<td>Workshops 1</td>
<td>Workshops 1</td>
<td>Workshops 1</td>
<td>Workshops 1</td>
<td>Workshops 1</td>
<td>Workshops 1</td>
</tr>
<tr>
<td>15:00-15:30</td>
<td>Coffee Break</td>
<td>Coffee Break</td>
<td>Coffee Break</td>
<td>Coffee Break</td>
<td>Coffee Break</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>15:30-17:00</td>
<td>Workshops 1</td>
<td>Workshops 1</td>
<td>Workshops 1</td>
<td>Workshops 1</td>
<td>Workshops 1</td>
<td>Workshops 1</td>
</tr>
<tr>
<td>17:00-18:00</td>
<td>Plenary Session 2</td>
<td>Plenary Session 2</td>
<td>Plenary Session 2</td>
<td>Plenary Session 2</td>
<td>Plenary Session 2</td>
<td>Plenary Session 2</td>
</tr>
<tr>
<td>18:00-20:00</td>
<td>Networking Event</td>
<td>Networking Event</td>
<td>Networking Event</td>
<td>Networking Event</td>
<td>Networking Event</td>
<td>Networking Event</td>
</tr>
<tr>
<td>20:00-21:00</td>
<td>Welcome Reception</td>
<td>Welcome Reception</td>
<td>Welcome Reception</td>
<td>Welcome Reception</td>
<td>Welcome Reception</td>
<td>Welcome Reception</td>
</tr>
</tbody>
</table>

**Date:** 8th - 12th October

**Location:** Chania, Crete, Greece

**Conference:** ESS / IESS Meeting 2019
Update on the « Personalized Randomized Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis » (PROVIDE) trial

The PROVIDE trial (ClinicalTrials.gov registration NCT03332225) is the first clinical trial aiming to assess the impact of immunotherapy according to personalized needs of the patient. The trial is sponsored by the Hellenic Institute for the Study of Sepsis and it is under the auspices of the European Shock Society. The trial has been running since December 2017 at 11 study sites in Greece (EudraCT 2017-002171-26; approval by the National Ethics Committee 78/17; approval by the National Organization for Medicines IS 75-17). In October 2018, the study was amended to open at three more sites so that the current count includes 14 participants (four departments of Internal Medicine and 10 Intensive Care Units).

The trial has a unique design; inclusion criteria are not limited to clinical characteristics but they take into consideration the immune state of the patient. To this end, adult patients with septic shock (by the Sepsis-3 classification) due to lung infection (CAP, HAP and VAP) or primary bacteremia or acute cholangitis are screened for eligibility using two consecutive measurements of ferritin and of HLA-DR/CD14 co-expression. Those with ferritin above 4,420 ng/ml are classified into macrophage-activation syndrome (MAS) and those with ferritin below 4,420 ng/ml but HLA-DR/CD14 less than 30% are classified into sepsis-induced immunosuppression. Enrolled patients are randomized through double-blind, double-dummy approach into the immunotherapy arm or the standard-of-care arm. Patients assigned into the immunotherapy arm receive treatment with either intravenous anakinra (targeting MAS) or subcutaneous recombinant IFNy (targeting immunosuppression). Patients assigned into the standard-of-care arm receive intravenous and subcutaneous placebo treatment. Main exclusion criteria are primary and secondary immunodeficiencies and solid and hematologic malignancies.

The PROVIDE trial is a real challenge for all participating investigators and for personnel who works in the central study lab. The challenge consists on the development of one high-level collaboration network having rapid exchange of information as the main goal so that patient screening is facilitated. This targets fast transportation of screening samples to the central lab, rapid processing and fast feedback report of blind information for allocation into treatment arm. Until November 14 2018, 166 patients under vasopressors were screened for eligibility; sixty-two patients were excluded due to study exclusion criteria and blood was sampled for immune state classification from 104 patients; 21 patients are enrolled in the study.

Members of the Hellenic Sepsis Study Group

Evangelos Giamarellos-Bourboulis
Biomarkers able to help the physicians to diagnose the presence of an infection (or sepsis) as early as possible, remain highly desired. Over 46,000 scientific papers relate to the quest for such biomarkers. Out of the hundreds of studied biomarkers, most of the reports show a significant difference \( (p<0.05) \) between infected patients and controls (1). However, a marked overlap between the individual values obtained from different groups of patients (i.e. inadequate specificity and/or sensitivity) does not support their routine use in clinical practice (2) (see below an example – data from the CAPTAIN study). The same is true for the most popular one (the only one), namely, procalcitonin (PCT) (3). The analysis of the cytokine storm mirrors the severity of the infection. The levels of certain biomarkers correlate with clinical scores (4-6) and those biomarkers have been proposed as markers of prognosis/outcome that can distinguish survivors versus non-survivors (7,8). Similar outcome-predictive claims can be made for markers of endothelial cell activation (9) as well as the intensity of thrombocytopenia (10), lymphopenia (11) and the number of circulating immature granulocytes (12). In addition to the proteomic approach, other analytes such as cell surface markers, micro-RNAs, metabolites and mRNAs have been investigated. Among the most promising cell surface markers, let us mention CD64 on neutrophils (13), and HLA DR (14) and CX3CR1 (15) on monocytes. However, a recent study revealed that no combination of leukocyte surface biomarkers has a predictive validity for the diagnosis of sepsis among patients with suspected acute infection (16). It is generally agreed that a magic marker does not exist and new trends favor a hunt for the appropriate combination of biomarkers. This is exemplified in the transcriptomic analysis where promising association of certain genes could help to discriminate subsets of patients and allow the diagnosis of sepsis (19-21). Similarly, metabolomic studies demonstrated the usefulness of measuring several metabolites for an accurate diagnosis of sepsis (22-24). In terms of proteomic, a recent study suggested that measurements of TRAIL, CXCL10 and CRP could help discriminating bacterial versus viral infections (25). The combinations of plasma and cell surface markers such as CRP and CD64 (26) or PCT, sTREM-1 and CD64 (27) have also led to efficient scoring system allowing identification of septic patients. Unfortunately, our own work that examined 53 various
biomarkers (plasma proteins, mRNAs, surface markers) has failed to define any marker combinations able to distinguish patients who had developed sepsis in the intensive care unit (ICU) (28). This negative finding most probably reflects the difficulty in finding specific markers of infection within a huge inflammatory background. In contrast, however, a similar approach in the emergency department could be more promising (ClinicalTrials.gov, NCT02707718).

Most interesting is also the recent technological progress and new tools such as microfluidic that are now proposed as diagnostic support. Most promising reports have investigated cell surface markers with the microfluidic (29,30), and the neutrophil motility investigated by such devices reached 97% sensitivity & 98% specificity (31). Other methods, for example detection of microbial markers with molecular approaches are also under investigation (32). Of note, a meta-analysis of the septi-fast test (Roche) revealed 68.8% sensitivity [range : 25.6 – 95.2] and a 85.2% specificity [range : 50 – 98.7]. Excessive sensitivity of a test can be, however, misleading. A recent report on the next-generation DNA sequencing (NGS) technology - based 16S ribosomal RNA amplicon sequencing combined with Genome Search Toolkit, showed positive readouts in samples from healthy people (33).

To conclude, many promising measurements are now available, however, they still need to be validated depending of the studied population (neonates, infants, children, adults, elderlies) the type of infection (viral, fungal, parasitic, bacterial) and the site of infection. While certain combination of biomarkers could help to identify infected patients among people with fever of an unknown origin, the key challenge remains: to quickly and precisely identify patients with sepsis among patients suffering from various severe inflammatory disorders.

1. Parlato & Cavaillon, Methods Mol Biol 2015, 1237, 149-211
4. Liu et al. Inter J Infect Dis 2015, 40, 135
6. Almansa et al. Sci Reports 2018, 8, 11999
13. Livaditi et al. Cytokine 2006, 36, 283
14. Monneret Int. Care Med. 2006, 32: 1175-83
24. Mickiewicz et al. Sci Reports 2018, 8: 16606

Jean-Marc Cavaillon
International Expert Consensus Guidelines for Pre-Clinical Sepsis Studies Published

In May 2017, with support of AUVA and Lorenz-Böhler Trauma Hospital, our Ludwig Boltzmann Institute for Experimental and Clinical Traumatology (LBI) hosted a Wiggers-Bernard Conference entitled: “Pre-clinical Modeling in Sepsis: exchanging opinions and forming recommendations”. Over the period of three days (May 3-5), we had a privilege to host the crème de la crème of international experts (31 participants from 13 different countries) in clinical and pre-clinical sepsis. The conference was organized with the goal to identify the limitations of pre-clinical sepsis modeling and to formulate basic guidelines that would enhance the translational value of findings originating from those models. The conference was preceded by a significant preparatory workload; we conducted a literature review of the 260 most highly cited scientific articles on sepsis models published between 2003 and 2012 to gain insight into their strengths and weaknesses and to identify the key modeling areas to be discussed. We chose six specific thematic working groups to effectively streamline the workload: 1) Study design, 2) Humane modeling, 3) Infection types, 4) Organ failure/dysfunction, 5) Fluid resuscitation and 6) Antimicrobial therapy endpoints. The two conference days we had spent together in Vienna were very intense as we drafted a list of guideline points. The guidelines were then refined into the so called “Minimum Quality Threshold in Pre-Clinical Sepsis Studies” (MQTiPSS). Overall, we agreed on formulating/releasing the total of 29 recommendation and consideration points. The final outcome of our teamwork includes an open-access Executive Summary (simultaneously co-published in Shock, Infection and Intensive Care Medicine Experimental journals; PMID:30106875, 30225655, 30112605) to support its wide dissemination as well as three full-size papers (Parts 1-3; PMID:30106874; 30106873; 29923896) that provide details to the guideline points (to be published in the January issue of Shock).

Although the MQTiPSS has not received an official endorsement from relevant professional societies, we received plenty of support from those societies to disseminate the MQTiPSS worldwide. Four Shock societies (the US, Japanese, Chinese and European Shock Society), Deutsche Sepsis-Gesellschaft, European Society of Intensive Care Medicine (ESICM) and Latin American Sepsis Institute sent blast emails to their members and/or posted website notes. Additionally, thanks to ESICM (https://www.esicm.org/ictv-icmx-article-alert-pre-clinical-sepsis-
a short animation movie was produced to describe the entire concept in an approachable layman terms supported by a podcast and icTV (coming soon) interview. We strongly believe that the Wiggers-Bernard initiative has been a needed and positive step in the right direction. We also very much hope that MQTiPSS guideline points will be recognized as “best practices” and scientists will chose to implement them in their experimental works in order to enhance standardization across pre-clinical models of sepsis. The ultimate goal of the MQTiPSS is to improve translation of pre-clinical findings into clinics. We sincerely thank all those who have been supporting us in above effort either by action and/or encouraging words.

Marcin Osuchowski, coordinator of the Wiggers-Bernard Initiative
European Society of Intensive Care Medicine 31st Annual Congress, Paris

In October 2018, thousands of European (and beyond) critical care physicians, nurses and researchers met in Paris to participate at the ESICM annual congress. Leaving the numbers aside, it was a huge conference with multiple concomitant sessions and impressive industry booths. The strength of this particular congress seems to be a good balance between the talks given by the prominent researchers in the field and the ones based on the submitted abstracts. This selection strategy gave a great opportunity to listen to people with less known names but with interesting ideas and/or research to present. The topic covered all aspects of the current emergency and critical care medicine so it is pointless to refer to any specific topic. However, it is definitely worth to mention the vigorous pro-con discussion at the session dedicated to the new sepsis bundles. The joint session with the International Sepsis Forum provided an interesting talk from Marvin Singer who raised a stirring question whether all sepsis patients could be saved. Additionally, John Marshall gave an inspiring talk about the past and current concepts of sepsis. Experimental research topics were mainly gathered in separate sessions coordinated by the Intensive Care Medicine Experimental (ICMx) team and constituted an interesting mixture of good translational works as well as basic science on pathophysiology of various critical care conditions.

Among news from the clinical trials, it was interesting to learn about the results of the new immunoglobulin preparation (Trimodulin) trial in the community-acquired pneumonia that showed positive effects in a subgroup of patients with high CRP. Altogether, the meeting was a great platform for acquiring and exchanging the newest and “hot” knowledge in the field. Despite the lack of novel ground-breaking clinical trial results, participation in this event points out that we have been experiencing an interesting evolution in the approach to research and/or trials in critical care medicine.

Tomasz Skirecki
The SepsEast Forum ([http://sepseast2018.com/](http://sepseast2018.com/)) was organized on November 15-17, 2018, by prof. Zsolt Molnár, head of the Institute of Anesthesiology and Intensive Therapy at University of Szeged, Hungary for the 4th time in Budapest. The name of this congress refers to sepsis, as central point of interest for the attending anesthesiologists and intensivists and also to the concept of bringing East and West closer together. The scientific content was guaranteed by 30 invited speakers, influential opinion leaders of the field. SepsEast was dedicated to Ignác Semmelweis, Hungarian obsterician-physician, the “savior of mothers” who was born 200 years ago. It should be noted that quite remarkably the registration for junior doctors (under the age of 29) was free of charge.

The Forum comprised of 14 symposia and 2 e-poster sessions. The importance of detection and modulation of organ disfunction, timely assessment and balanced control of immune response as well as of individualized therapy during sepsis were emphasized in most of the symposia.

The attendees had chance to enjoy particularly entertaining lectures given by Didier Payen (“Time commands therapeutic interventions” - “Dysregulated host response”), Xavier Monet (“How to integrate hemodynamic variables to manage patients with septic shock” and “Weaning-induced cardiac disfunction”) and the futuristic lecture by Jean-Louis Vincent (on “The future ICU”). Can Ince presented views on personalized medicine – which should include personalized physiology-based medicine in the future (not based only on the detection of biomarkers). He showed promising experimental results as well, such as senescent cell apoptosis as a target, and the role of previous physical activity of patients which is influenced by myokines (including IL-6) in the outcome of sepsis. He also gave a very clear talk on microcirculation as a target of resuscitation (as usual).

As for therapeutic issues, Vsevolod Kozkov (Russia) gave a lecture about therapeutic pitfalls (with the title of “Ten don’s” of septic shock”) including dangers of fluid, vasopressor, ankaalyzing therapy, immunoglobulins, steroids, hypercholaemia (induced by saline), and early use of hemofiltration and albumin, and also about benefits of antibiotics which also enter the extravascular space. The congress president (prof. Molnár) presented his experiences with adjunctive therapies (such as immunoglobulins and cytokine absorption with CytoSorb) and “restrictive” fluid management of patients with the ROSE approach (also preventing the degradation of glycocalyx). Modulation of the immunological changes and the benefits of epirubucin in modulating the immunological response during sepsis with neutrocytosis and those of interferon-gamma during the immunosuppression phase were presented by Didier Payen.
A loud and highly entertaining concert was closing the Forum. In the band called “OnCall” the congress president himself was the guitarist/singer while the head of the Department of Emergency Medicine of the same university secured the necessary rhythm as drummer.

Andrea Szabó

Introducing ESS research groups: From macro- and microcirculations to cellular energetics: the Surgical Research Group in Szeged

Introduction
The Institute for Surgical Research (ISR) was established in 1951 by Dr. Gabor Petri (an internationally-recognized Hungarian surgeon of that time) with the major aim to teach basic surgical techniques as part of the graduate medical curriculum. Another aim was to provide support for investigative clinical surgery with basic research facilities and access to in vivo models. In this respect, the institute was the first of its kind in Hungary with strongly acknowledged “translational” purposes. Of note, dr. Sándor Nagy, second director of the institute, was also among the founders of the European Shock Society in 1983.

The Team
The current ISR director, prof. Mihály Boros served as a member of the Executive Committee of ESS and today he is one of the trustees, while assoc. prof. Andrea Szabó is a member of the ESS Executive Committee. Since its foundation, the ISR research programs are focused on a teamwork culture that integrates clinicians, full time surgical-scientists, PhD students and undergraduate medical students. Our students regularly participate at local and international congresses; many of them competitive award recipients (e.g. ESS and ESSR awards). In 2015, a new mentorship system was introduced at the University of Szeged, named after Albert Szent-Györgyi, a Nobel-prize laureate and former Dean of our Faculty. The goal of the Szeged Scientists Academy School is to support talented students who are willing to conduct high-level laboratory research incorporated into their regular curriculum. The students meet regularly (at least twice a year) with Nobel laureates discussing the new results during special workshops (see details at http://www.nobel-szeged.hu/eng/index.php). The mentoring and recruitment program was recently extended towards secondary school students; as of today, we work together with 4 medical and 2 secondary school students of the Academy.

Main Research Groups and Topics
The Mitochondrion Group investigates the consequences of hypoxia/anoxia and inflammation (including arthritis and inflammatory bowel disease) at subcellular level using high resolution respirometry (Oroboros Instruments). Mitochondrial manifestations of injury are investigated in different organs (liver, kidney, bowels, heart and synovial membranes) in clinically-relevant animal models of ischemia/reperfusion, sepsis and autoimmune diseases.
During the last decade, a particular interest was focused on the detection of hypoxia-induced oxido-reductive stress reactions and modulation of the consequences by exogenous methane administration in a variety of in vivo and in vitro models. (for potential cooperation please contact hartmann.petra@med-u-szeged.hu, juhasz.laszlo@med.u-szeged.hu)

The Macrohemodynamics Group focuses on different regulatory aspects of circulatory pathologies in animal models of human diseases. The main topics of interest are sepsis-induced alterations, cardiogenic shock and extracorporeal perfusion. Regarding sepsis, the consequences of complement cascade blockade, antagonism of endothelin and NMDA receptors, and goal-directed fluid therapy (with special emphasis on sepsis-induced glycocalyx degradation) are studied. The group has developed new models to investigate the pathomechanism of non-occlusive splanchnic ischemia (by pericardial tamponade in minipigs). The unwanted peripheral (kidney) consequences of extracorporeal perfusion (including ECMO) are also studied in large animals, more specifically, the therapeutic possibilities of complement C5a antagonism and administration of gaseous transmitters (e.g. methane) are examined. The available methodology includes complete hemodynamic monitoring including cardiac functions and perfusion of individual organs in mechanically ventilated and non-ventilated animal models. (for potential cooperation please contact kaszaki.jozsef@med.u-szeged.hu, varga.gabriella.1@med.u-szeged.hu)

The Microcirculation Group conducts examinations of the microcirculatory consequences of typical surgical scenarios in animal models and patients. Current research topics are ischemia/reperfusion syndromes (in animals: bowel, limb, liver, testis, urinary bladder, periosteum, synovial membrane; in humans: maxillofacial flaps) and sepsis (local and systemic inflammatory reactions in intra-abdominal sepsis in rodents and minipigs), with particular interest in the integrity of endothelial glycocalyx. We routinely employ traditional fluorescence intravital microscopy, orthogonal polarization spectral imaging, incident dark field imaging as well as confocal laser scanning microscopy and laser-Doppler flowmetry. (for potential cooperation please contact szabo.andrea.exp@med.u-szeged.hu)
Journal Club: What is new in shock/sepsis research?

Highlights of remarkable findings recently published in shock research

The “Master-Switch” in sepsis-induced immunoparalysis?

**Source:** Seeley JJ et al. Induction of innate immune memory via microRNA targeting of chromatin remodelling factors; Nature 2018, 559(7712):114-119 (link to the paper)

**Main important messages:**
Sepsis is associated with the development of immunoparalysis that enhances the risk for secondary infections or for infection persistence. During immunoparalysis, the capacity of monocytes to respond to microbial stimulation with the secretion of inflammatory cytokines is abrogated. The mechanisms underlying this monocyte reprogramming are still incompletely understood. Previous studies have shown that there does not exist a single mediator (e.g. IL-10) that is responsible for the broad changes of the immune system. Rather, an upstream “Master-Switch” might turn off the expression of inflammatory genes in monocytes from septic patients. A study from J.J. Seeley et al. recently published in “Nature” sheds some light on this unresolved issue. Since LPS tolerance mimics some aspects of immunoparalysis during sepsis they initially investigated molecular changes in macrophages during LPS tolerance in vitro. Using diverse experimental approaches they discovered that the microRNAs miR-222 and miR-221 are highly expressed in tolerized macrophages and inhibit the transcription of inflammatory genes. miR-222 and miR-221 did not exert their suppressive effect through binding to the promoter of the inflammatory genes but instead to the promoter of brg1. BRG1 is the catalytic subunit of the SWI/SNF complex that mediates chromatin remodeling to enable the recruitment of transcription factors to the DNA of several inflammatory genes. Accordingly, in the absence of miR-222 and miR-221 there was enhanced recruitment of BRG1 and STAT transcription factors to the promoter of inflammatory genes and release of inflammatory cytokines. Using mir222/mir221 knockout mice the authors showed that miR-222 and miR-221 broadly suppressed inflammation and innate immune function. Most importantly with regard to the development of immunoparalysis mononuclear cells from septic patients expressed increased levels of miR-222 and miR-121 during sepsis that inversely correlated with the expression of BRG1 and that was associated with organ failure. Thus, the authors suggest that miR-222/miR-221 on the one hand protect from overwhelming inflammation (e.g. in LPS shock) and on the other hand mediate organ damage and mortality during sepsis. In my opinion, miR-122/miR-121 might represent a “Master-Switch” during sepsis and are worth to be evaluated as a therapeutic target in clinically relevant sepsis models.

**Written by:** Stefanie Flohe, Essen, Germany
Upcoming events

48th Critical Care Congress
February 17-20, 2019
San Diego Convention Center
San Diego, California, USA

https://www.sccm.org/Education-Center/Annual-Congress

39th International Symposium on Intensive Care and Emergency Medicine
March 19-22, 2019
Brussels, Belgium
https://www.intensive.org/1/main.asp

20th ESTES Congress 2019
May 5-7, 2019
Prague, Czech Republic


Sepsis 2019
May 09-10, 2019
Rio de Janeiro, Brazil
http://internationalsepsisforum.com/activities/sepsis-20xx/

TERMIS European Chapter Meeting 2019
27th-31st May 2019
Rhodes, Greece
https://www.termis.org/eu2019/
42nd Shock Society 2019 Annual Conference, June 8-11, 2019
(Co-located with the 39th SIS Annual Meeting, June 5-8, 2019)
Coronado, CA

http://shocksocociety.org/Meetings.aspx

2019 RDCR SYMPOSIUM
June 23-26, 2019
Bergen, Norway
https://rdcr.org/

32nd European Annual Congress on Surgical Infections
June 26-18, 2019
Dublin, Ireland
http://sis-e.org/2019/

Weimar Sepsis Update 2019 - "Tribute to Translation"
September 11-13, 2019
Weimar, Germany
http://www.sepsis-gesellschaft.de/

19th ESOT Congress 2019
September 15-18, 2019
Copenhagen, Denmark
https://www.esot.org/EDTCO/home

32nd Annual Congress
Berlin
https://www.esicm.org/events/32nd-annual-congress-berlin/

32nd ESICM-LIVES 2019
September 28 –
October 2, 2019
Berlin, Germany

Back to Contents
18th ESS Congress/ 9th IFSS Congress  
October 8-10, 2019  
Chania, Crete, Greece  
Conference Center: Avra Imperial Hotel

[Image: https://www.aegeanconferences.org/src/App/conferences/view/138]

World Federation of Societies of Intensive and Critical Care Medicine: 14th World Congress  
October 14-18, 2019 Melbourne, Australia


Future Meetings

43rd Annual Conference on Shock  
June 6 - 9, 2020  
Toronto, Canada

[Image: Future Meetings Image]

Back to Contents
The Executive Committee of the ESS

The President:

Markus Huber-Lang, MD
Professor and Chair
Institute for Clinical and Experimental Trauma-Immunology
University Hospital of Ulm
Helmholtzstr. 8/1
89081 Ulm, Germany
Phone: +49-731-500-54801
Fax: +49-731-500-54718
e-mail: markus.huber-lang@uniklinik-ulm.de

The Past-President:

Jean- Marc Cavaillon, PhD, Dr.Sc.
Department of Infection and Epidemiology
Institut Pasteur
25-28 rue du Docteur Roux
75015 Paris, France
Phone: +33 1 45 68 82 38
Fax: +33 1 40 61 30 42
e-mail: jean-marc.cavaillon@pasteur.fr

The President-Elect: [elected 2017]

Evangelos J. Giamarellos-Bourboulis, MD, PhD
4th Department of Internal Medicine
ATTIKON University Hospital
1 Rimini Str
12462 Athens, Greece
Phone: +30 210 58 31 994
Fax: +30 210 53 26 446
e-mail: egiamarel@med.uoa.gr
The General Secretary:

Inge Bauer, PhD
Dept of Anaesthesiology
Duesseldorf University Hospital
Moorenstraße 5
40225 Duesseldorf, Germany
Phone: +49 211 81 12053
Fax: +49 211 81 015 12053
e-mail: Inge.Bauer@med.uni-duesseldorf.de

The Treasurer:

Marcin F. Osuchowski, DVM, PhD
Ludwig Boltzmann Institute for Experimental and Clinical Traumatology
Donaueschingenstrasse 13
1200 Vienna, Austria
Phone: +43-1-33110 469
Fax: +43-1-33110 460
e-mail: marcin.osuchowski@trauma.lbg.ac.at

The Elected Councillors:

Stefanie Flohé, PhD
Essen University Hospital
Research Group Immunology Sepsis/Trauma
Dept. of Orthopaedics and Trauma Surgery
Virchowstr. 171
45147 Essen, Germany
Phone: +49 201 / 723-4405
Fax: +49 201 / 723-5226
e-mail: stefanie.flohe@uk-essen.de

Artem N. Kuzovlev, MD, PhD
V.A. Negovsky Research Institute of General Reanimatology of the Russian Academy of Medical Sciences
25 Petrovka str., build. 2
107031 Moscow, Russia
Phone: +79261887641 (mob)
e-mail: artem_kuzovlev@mail.ru

Back to Contents
Marc Maegele, MD  
Department of Trauma and Orthopedic Surgery  
Institute for Research in Operative Medicine (IFOM)  
Cologne-Merheim Medical Center (CMMC), University of Witten/Herdecke  
Ostmerheimer Str. 200  
51109 Cologne, Germany  
Phone: +49 221/8907-13614  
Fax: +49 221/8907-3085  
e-mail: Marc.Maegele@t-online.de

Tomasz Skirecki, MD, PhD  
Department of Anesthesiology and Intensive Care  
Laboratory of Flow Cytometry  
The Center of Postgraduate Medical Education  
Marymocnka 99/103  
01-813 Warsaw, Poland  
Phone: +48 693 990 700  
e-mail: tskirecki@gmail.com

Andrea Szabó, MD, PhD  
Institute of Surgical Research  
University of Szeged  
Szeged, Hungary  
Szőkefalvi-Nagy B. u. 6.  
H-6720 Szeged, Hungary  
Phone: +36 62 545 106  
Fax: +36 62 545 743  
e-mail: szabo.andrea.exp@med.u-szeged.hu

The Editor-in-Chief of SHOCK®:  
Irshad H. Chaudry, PhD  
Dept of Surgery, University of Alabama-Birmingham  
1530 3rd Avenue South  
Birmingham, AL 35294-0012, USA  
Phone: 001 205 975 0118  
Fax: 001 205 975 0119  
e-mail: ichaudry@uabmc.edu
Councillors (appointed by the President)

Borna Relja, PhD
Dept. of Trauma, Hand- and Reconstructive Surgery
University Hospital Frankfurt
Goethe-University
Theodor-Stern-Kai 7
60590 Frankfurt am Main, Germany
Phone: +49 69 6301 84372
Fax: +49 69 6301 5854
e-mail: info@bornarelja.com

Fabienne Venet, PharmD, PhD
EA 7426 Physiopathology of Injury-Induced Immunosuppression - PI3
Immunology Laboratory, Hospices Civils de Lyon
Edouard Herriot Hospital
5 place d'Arsonval
69437 LYON Cedex 03, France
Phone: +33 4 72 11 95 46 / +33 4 72 11 97 46
Fax: +33 4 72 11 97 53
e-mail: fabienne.venet@chu-lyon.fr

Auditors:

Sina M. Coldewey, MD, PhD
Dept. of Anaesthesiology and Intensive Care Medicine
University Hospital Jena
Erlanger Allee 101
D-07747 Jena
Phone: +49 3641 9323190
e-mail: sina.coldewey@med.uni-jena.de

Mihály Boros, MD, PhD, DSc
Institute of Surgical Research
University of Szeged
Szőkefalvi-Nagy B. u. 6.
H-6720 Szeged, Hungary
Phone: +36 62 545-102
e-mail: boros.mihaly@med.u-szeged.hu
Invitation to publish in Shock®

Shock is a monthly journal that publishes the results of investigations in the field of injury, inflammation and sepsis; of clinical and laboratory origin alike (current IF=3.005). It is the official Journal of all international Shock Societies, including ESS. Thanks to its efficient reviewing process, you will typically have your submitted paper reviewed within 15 days. So do not hesitate, submit your next best results to SHOCK!

ESS Membership

Dear ESS members,
please kindly pay your ESS membership for 2018/19. Currently, a fixed 2-year membership fee of EUR 100 for regular members and EUR 50 for student members applies.

We sincerely appreciate your contribution; please do not ignore this important commitment. We are happy to receive your funds at:

European Shock Society
IBAN: AT13 1420 0200 1093 6552
BIC: EASYATW1

Please identify your transfer with your first/last name and a "full/student ESS membership fee" annotation.

Thank you!
Last words about the ESS newsletter

Dear present ESS member,

If you like your ESS Winter Newsletter, please feel free to share it with your colleagues in the lab, department and/or institute. Perhaps, you could use this opportunity to suggest them to join us (a registration form can be found at the end of this Newsletter). Do not forget that we need you to keep improving our society so it stands proud and strong among other international Shock Societies.

This Newsletter, put together by your peers, belongs to you! We invite you to identify with it as members of the ESS. Moreover, we ask you to help us make it even better. Accordingly, we would be delighted to publish in our next issue any input you might be wishing to share with us (e.g. discussion on a given research/popular science topic, announce available positions in your lab, a contribution to the journal club corner, historical memories, comments about sepsis 3.0 etc.)

Dear past ESS member,

Please do not forget to renew your membership. We need all colleagues, junior and senior alike, to enable the ESS to host in its ranks the best representatives of the European Shock research - at the bedside and/or at bench alike.

Markus Huber-Lang
ESS Membership application form

(http://www.europeanshocksoociety.org/register)